Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Overview
Perrigo Company Plc (PRGO) is a foremost global provider of over-the-counter consumer self-care products and affordable health solutions. With roots dating back to 1887, the company has evolved from packaging generic home remedies to a focused, pure-play consumer self-care business, specializing in a wide range of products from infant formulas to branded over-the-counter healthcare solutions.
Core Business and Product Portfolio
Perrigo operates across a spectrum of product categories that include store brand offerings and nationally recognized branded products. Its portfolio covers key segments such as infant formula for store brands, branded OTC products, and innovative health solutions like its pioneering over-the-counter daily birth control pill. With a robust blend of store brand and national brands, Perrigo’s business model is anchored on providing quality, accessible healthcare options that empower individuals to manage minor health conditions effectively.
Market Position and Global Presence
Positioned as one of the largest consumer health companies, Perrigo’s operations extend primarily across North America, Europe, Australia, and strategic markets in Asia and the Middle East. Its extensive distribution network includes major retailers such as Walmart, Amazon, Costco, and CVS, underscoring a resilient and expansive market reach. The company’s commitment to 'quality affordable healthcare products' is reflected in its tailored approach to meet diverse consumer needs, offering products that blend trusted efficacy with competitive pricing.
Business Model and Strategic Initiatives
Perrigo’s revenue is driven by a well-diversified product mix that leverages both private-label and branded offerings. Its transformation into a pure-play consumer self-care company was achieved through strategic divestments in areas such as animal health and generic pharmaceuticals, allowing a sharper focus on consumer self-care. The integrated business model maximizes profitability by reinvesting savings through operational efficiency programs and strengthening high-growth segments. Initiatives aimed at innovation and operational streamlining, such as the globally recognized Project Energize, underscore its commitment to maintaining competitive cost structures and enhancing product margins.
Innovation and Consumer-Focused Strategy
Innovation remains a cornerstone of Perrigo’s strategy. The company continuously invests in new product launches and refinements that align with evolving consumer needs and regulatory changes. Its recent advancements in the reproductive health space—exemplified by partnerships that enhance health education and access—demonstrate a commitment to addressing critical areas of consumer well-being. Such initiatives not only reinforce brand strength but also contribute to market differentiation within the competitive landscape of OTC health and wellness solutions.
Industry Expertise and Differentiation
Perrigo’s long-established presence and expertise in the consumer health arena are backed by decades of operational excellence and strategic leadership. The company’s ability to consistently deliver high-quality, affordable products positions it uniquely among its peers. Detailed management succession plans and operational transitions further exemplify its robust internal expertise and focus on sustaining long-term value creation. By harnessing a blended-branded approach, Perrigo successfully addresses various consumer demographics, ensuring accessibility to essential health products across multiple price points.
Conclusion
Overall, Perrigo Company Plc remains an influential force in the global consumer self-care market. Its commitment to quality, affordability, and continuous innovation serves as a testament to its proven business model. For investors and market analysts alike, Perrigo offers a comprehensive case study in achieving market resilience and operational excellence in a rapidly evolving healthcare landscape.
Perrigo Company plc (NYSE: PRGO) announced that Rich Sorota, EVP and President of Consumer Self-Care Americas, will present at the ICR Conference on January 11, 2021, at 11:30 AM EST. Additionally, CEO Murray S. Kessler and CFO Ray Silcock will present at the J.P. Morgan Global Healthcare Conference on January 13, 2021, at 3:40 PM EST. Both presentations can be accessed via webcasts. Perrigo is a leading provider of self-care products and is the largest store brand OTC player in the U.S., with over 9,000 SKUs. More details can be found on their investor relations website.
Perrigo Company plc (NYSE; TASE: PRGO) will present at the Morgan Stanley Global Consumer & Retail Conference on December 1, 2020, at 1:00 PM EST. CEO Murray S. Kessler and CFO Ray Silcock will lead the presentation, which will be accessible via webcast. Perrigo is a leading provider of affordable self-care products, ranking as the largest store brand OTC player in the U.S. and a top 5 OTC company in Europe. The company focuses on enhancing consumer wellness and offers over 9,000 SKUs under various brand labels.
Perrigo Company reported Q3 2020 net sales of $1.2 billion, up 1.3% year-over-year, driven by robust growth in its Consumer Self-Care segment. The company achieved record net sales of $664 million in Consumer Self-Care Americas, a 7.3% increase, while organic net sales grew 1.6%. Despite challenges, including a $202 million goodwill impairment and a diluted net loss per share of $1.13, Perrigo reaffirmed its fiscal outlook for 2020, projecting net sales growth of 6-7% and adjusted EPS of $3.95-$4.15. The company remains optimistic about its self-care evolution and e-commerce strategy.
Perrigo Company plc (NYSE: PRGO) announced a ruling from the Irish High Court stating that the issuance of a Notice of Amended Assessment by Irish Revenue in November 2018 did not violate the company's legitimate expectations. No payment is required due to this ruling. However, the High Court did not quash the assessment, allowing Perrigo to either appeal the decision or challenge the assessment's merits before the Irish Tax Appeals Commission. The company maintains that the assessment is without merit and remains committed to defending its position.
Perrigo Company plc (NYSE: PRGO) has acquired three OTC skincare brands—Emolium®, Iwostin®, and Loxon®—from Sanofi, marking a significant step in its transformation into a consumer-focused self-care company. This acquisition aims to tap into growth opportunities in Eastern Europe and is expected to enhance Perrigo's existing product portfolio. Executive VP Svend Andersen emphasized the strategic importance of leveraging high-quality skincare and expanding into new markets. The company is a major player in the OTC sector, with over 9,000 SKUs under store brand labels in the U.S. and a strong presence in Europe.
Steripod, a brand under Perrigo Company plc (NYSE: PRGO), emphasizes the importance of hygiene during the holiday season amidst COVID-19 concerns. The Steripod Toothbrush Protector offers protection against airborne contaminants, ensuring safe travel and hygiene practices. This product, infused with natural Thymol vapors, keeps toothbrushes clean for up to three months. Travelers are encouraged to adopt additional safety measures such as masks and sanitizers to prevent illness. For more information, visit getsteripod.com.
Perrigo Company plc (NYSE: PRGO) announced a scheduling update for its third quarter financial results call to November 4, 2020, at 4:30 p.m. (EST), following a notice from the Irish High Court regarding a pending judicial review of a €1.6 billion assessment by Irish Revenue. The company asserts the assessment is without merit and intends to challenge it. The outcomes of the court's decision may influence the company's financial implications, and no payment is required until all determinations are resolved.
Perrigo Company plc (NYSE; TASE: PRGO) has declared a quarterly dividend of $0.225 per share, set to be paid on December 15, 2020. Shareholders of record by November 27, 2020 will be eligible for this payment. Perrigo is recognized for providing Quality, Affordable Self-Care Products, leading in the OTC market with over 9,000 SKUs. Despite broader economic uncertainties due to COVID-19, the company maintains a strong position in the consumer health sector.
Perrigo Company plc (NYSE: PRGO) will release its third quarter financial results on November 4, 2020. A conference call is scheduled for 8:00 a.m. (EST) on the same day, allowing investors to engage and hear insights directly from the management. Perrigo is recognized as a leading provider of Quality, Affordable Self-Care Products and is the largest store brand OTC player in the U.S. The company also has a significant presence in Europe, ranking among the top five OTC companies by revenue.
Perrigo Company plc (NYSE; TASE: PRGO) announced a voluntary recall of albuterol sulfate inhalation aerosol due to clogging complaints. This follows the halting of production and distribution. The recall is part of corrective actions, but a timeline for reintroduction is not set. The company anticipates a charge of approximately $18 million to $22 million in Q3 2020 but maintains its fiscal year 2020 adjusted EPS guidance of $3.95 to $4.15, attributing stability to strong consumer demand in its self-care segments. Sales of the inhalation aerosol ceased in late August 2020.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
What products does Perrigo offer?
How has Perrigo evolved over the years?
What is Perrigo's core business model?
Which markets are key to Perrigo's global presence?
How does Perrigo differentiate itself from competitors?
What recent innovations has Perrigo introduced?
How does Perrigo maintain its commitment to affordable healthcare?
What strategic initiatives support Perrigo's business transformation?
